PMID- 37197770
OWN - NLM
STAT- MEDLINE
DCOM- 20230519
LR  - 20230522
IS  - 1600-0617 (Electronic)
IS  - 0905-9180 (Print)
IS  - 0905-9180 (Linking)
VI  - 32
IP  - 168
DP  - 2023 Jun 30
TI  - Efficacy and safety of gefapixant for chronic cough: a meta-analysis of 
      randomised controlled trials.
LID - 10.1183/16000617.0219-2022 [doi]
LID - 220219
AB  - BACKGROUND: The efficacy and safety of gefapixant in adults with chronic cough 
      remain unclear. Our objective was to assess the efficacy and safety of gefapixant 
      using updated evidence. METHODS: MEDLINE, Cochrane Central Register of Controlled 
      Trials (CENTRAL) and Embase databases were searched from inception through 
      September 2022. Subgroup analysis based on dose of gefapixant (i.e. </=20, 45-50 
      and >/=100 mg twice daily for low, moderate and high doses, respectively) was 
      performed to explore a potential dose-dependent effect. RESULTS: Five studies 
      involving seven trials showed the efficacy of moderate- or high-dose gefapixant 
      for reducing objective 24-h cough frequency (estimated relative reduction 30.9% 
      and 58.5%, respectively) (i.e. primary outcome) and awake cough frequency 
      (estimated relative reduction 47.3% and 62.8%, respectively). Night-time cough 
      frequency was only reduced with high-dose gefapixant. Consistently, the use of 
      moderate- or high-dose gefapixant significantly alleviated cough severity and 
      improved cough-related quality of life, but increased the risk of all-cause 
      adverse events (AEs), treatment-related AEs and ageusia/dysgeusia/hypogeusia. 
      Subgroup analysis showed dose dependency in both efficacy and AEs with a cut-off 
      dose being >/=45 mg twice daily. CONCLUSIONS: This meta-analysis revealed 
      dose-dependent efficacy and adverse effects of gefapixant against chronic cough. 
      Further studies are required to investigate the feasibility of moderate-dose 
      (i.e. 45-50 mg twice daily) gefapixant in clinical practice.
CI  - Copyright (c)The authors 2023.
FAU - Chuang, Min-Hsiang
AU  - Chuang MH
AUID- ORCID: 0000-0002-8538-4861
AD  - Department of Internal Medicine, Chi Mei Medical Center, Tainan City, Taiwan.
AD  - Both authors contributed equally.
FAU - Chen, I-Wen
AU  - Chen IW
AD  - Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan City, 
      Taiwan.
AD  - Both authors contributed equally.
FAU - Chen, Jen-Yin
AU  - Chen JY
AUID- ORCID: 0000-0003-2313-5701
AD  - Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan.
FAU - Kang, Fu-Chi
AU  - Kang FC
AD  - Department of Anesthesiology, Chi Mei Medical Center, Chiali, Tainan City, 
      Taiwan.
FAU - Ho, Chun-Ning
AU  - Ho CN
AD  - Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan.
FAU - Wu, Shao-Chun
AU  - Wu SC
AUID- ORCID: 0000-0002-0984-6921
AD  - Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung 
      University College of Medicine, Kaohsiung City, Taiwan.
FAU - Yew, Ming
AU  - Yew M
AD  - Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan.
FAU - Lan, Kuo-Mao
AU  - Lan KM
AD  - Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan City, 
      Taiwan.
FAU - Hung, Kuo-Chuan
AU  - Hung KC
AD  - Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan 
      ed102605@gmail.com.
AD  - School of Medicine, College of Medicine, National Sun Yat-sen University, 
      Kaohsiung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20230517
PL  - England
TA  - Eur Respir Rev
JT  - European respiratory review : an official journal of the European Respiratory 
      Society
JID - 9111391
RN  - 6K6L7E3F1L (Gefapixant)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Chronic Disease
MH  - *Cough/drug therapy
MH  - Pyrimidines/adverse effects
MH  - *Quality of Life
MH  - Sulfonamides/adverse effects
MH  - Randomized Controlled Trials as Topic
PMC - PMC10189640
COIS- Conflict of interest: The authors declare no conflicts of interest.
EDAT- 2023/05/18 01:07
MHDA- 2023/05/19 06:42
PMCR- 2023/05/17
CRDT- 2023/05/17 20:32
PHST- 2022/11/08 00:00 [received]
PHST- 2023/02/27 00:00 [accepted]
PHST- 2023/05/19 06:42 [medline]
PHST- 2023/05/18 01:07 [pubmed]
PHST- 2023/05/17 20:32 [entrez]
PHST- 2023/05/17 00:00 [pmc-release]
AID - 32/168/220219 [pii]
AID - ERR-0219-2022 [pii]
AID - 10.1183/16000617.0219-2022 [doi]
PST - epublish
SO  - Eur Respir Rev. 2023 May 17;32(168):220219. doi: 10.1183/16000617.0219-2022. 
      Print 2023 Jun 30.